Dr. Joseph J. Drabick, MD

Dr. Drabick practices at Penn State Health Milton S. Hershey Medical Center in Hershey, Pennsylvania, part of Penn State.

Dr. Drabick's NPI, 1104875871, was assigned on May 9, 2006. Dr. Drabick graduated from Jefferson Medical College of Thomas Jefferson University in 1983. Dr. Drabick holds Pennsylvania license MD036289E.

Dr. Drabick's primary practice is Penn State Health Milton S. Hershey Medical Center, at 500 University Drive, Hershey, PA 17033 in Dauphin County. The practice phone is (717) 531-8521.

Dr. Drabick's primary practice is Penn State Health Milton S. Hershey Medical Center in Hershey, Pennsylvania, part of Penn State. Dr. Drabick is also affiliated with Penn State Health Holy Spirit Medical Center. The medical group on file is Penn State Health Milton S. Hershey Medical Center. Dmand AI also links Dr. Drabick to 2 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Drabick practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Drabick's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Drabick is licensed in Pennsylvania.

CMS data shows 654 Medicare services from Dr. Drabick across 6 procedure codes in 2024, for 231 Medicare patients. Medicare paid $51,051 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 231 Medicare patients who saw Dr. Drabick in 2024. The largest group is 65 to 74, with 95 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.47, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Drabick's median patient age at 73, with 39% women.

In 2024, Dr. Drabick wrote 494 Medicare Part D claims for 99 patients. 73% of them were for generic drugs. CMS names the drug for 392 of them, across 16 drugs with 11 or more claims each, at $752,539 in total drug cost. In 2023, CMS named 303 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Drabick for performance year 2024, reported as part of a group. Dr. Drabick accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 71 papers to Dr. Drabick, published from 2010 to 2025. 2018 was the busiest year, with 9. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Melanoma and Skin Neoplasms. Dr. Drabick has published most often in Cancer Biol Ther. Dr. Drabick's most frequent co-authors are Monika Joshi, MD, Sheldon Holder, MD and Heath Brandon Mackley, MD.

Dmand AI links Dr. Drabick to 10 clinical trials, 4 of them phase 1/2 studies. 5 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Carcinoma, Renal Cell. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 94 general payments to Dr. Drabick from 31 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 84% of the total. Sanofi and Genzyme US Companies paid the most, $51,069.

Dr. Drabick graduated from Jefferson Medical College of Thomas Jefferson University in 1983.